Johnson & Johnson (NYSE:JNJ) Shares Sold by Goldstream Capital Management Ltd

Goldstream Capital Management Ltd lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 56.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,582 shares of the company’s stock after selling 3,289 shares during the period. Johnson & Johnson accounts for approximately 0.1% of Goldstream Capital Management Ltd’s portfolio, making the stock its 27th biggest position. Goldstream Capital Management Ltd’s holdings in Johnson & Johnson were worth $373,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $32,000. Finally, Conquis Financial LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on JNJ shares. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $171.82.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 2.3 %

Shares of NYSE:JNJ opened at $157.42 on Monday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm’s 50 day moving average price is $159.49 and its 200 day moving average price is $154.95. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market cap of $379.37 billion, a price-to-earnings ratio of 23.67, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.30%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.